133 related articles for article (PubMed ID: 11266718)
1. CTLA4Ig-induced linked regulation of allogeneic T cell responses.
Lee RS; Rusche JR; Maloney ME; Sachs DH; Sayegh MH; Madsen JC
Transplant Proc; 2001; 33(1-2):88-9. PubMed ID: 11266718
[No Abstract] [Full Text] [Related]
2. CTLA4Ig-induced linked regulation of allogeneic T cell responses.
Lee RS; Rusche JR; Maloney ME; Sachs DH; Sayegh MH; Madsen JC
J Immunol; 2001 Feb; 166(3):1572-82. PubMed ID: 11160198
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of human anti-pig T cell response by anti-CD2, anti-CD40L, and CTLA4-Ig: a comparative study.
Xu Y; Ryan D; Wu C; Bazin H; Latinne D; White-Scharf ME; Thall AD
Transplant Proc; 2000 Aug; 32(5):926. PubMed ID: 10936275
[No Abstract] [Full Text] [Related]
4. Transplantation and the CD28/CTLA4/B7 pathway.
Alegre M; Fallarino F; Zhou P; Frauwirth K; Thistlethwaite J; Newell K; Gajewski T; Bluestone J
Transplant Proc; 2001; 33(1-2):209-11. PubMed ID: 11266782
[No Abstract] [Full Text] [Related]
5. CD28-B7 T cell costimulatory blockade by CTLA4Ig in the rat renal allograft model: inhibition of cell-mediated and humoral immune responses in vivo.
Akalin E; Chandraker A; Russell ME; Turka LA; Hancock WW; Sayegh MH
Transplantation; 1996 Dec; 62(12):1942-5. PubMed ID: 8990393
[TBL] [Abstract][Full Text] [Related]
6. Blockade of multiple costimulatory receptors induces hyporesponsiveness: inhibition of CD2 plus CD28 pathways.
Woodward JE; Qin L; Chavin KD; Lin J; Tono T; Ding Y; Linsley PS; Bromberg JS; Baliga P
Transplantation; 1996 Oct; 62(7):1011-8. PubMed ID: 8878397
[TBL] [Abstract][Full Text] [Related]
7. Tolerating differences.
Sikorski R; Peters R
Science; 1999 Jul; 285(5426):357-8. PubMed ID: 10438301
[No Abstract] [Full Text] [Related]
8. Autoantibodies to CTLA-4 enhance T cell proliferation.
Matsui T; Nishioka K; Kato T; Yamamoto K
J Rheumatol; 2001 Jan; 28(1):220-1. PubMed ID: 11196536
[No Abstract] [Full Text] [Related]
9. Suppression of T-cell-dependent immune responses in monkeys by CTLA4Ig.
Cabrian KM; Berry KK; Shuford WW; Mittler RS; Rodgers JN; Linsley PS
Transplant Proc; 1996 Dec; 28(6):3261-2. PubMed ID: 8962265
[No Abstract] [Full Text] [Related]
10. Transplantation of anergic histoincompatible bone marrow cells.
de Carvalho Bittencourt M; Tiberghien P; Saas P
N Engl J Med; 1999 Sep; 341(14):1081-2. PubMed ID: 10507928
[No Abstract] [Full Text] [Related]
11. CTLA4ig induces long-term graft survival of allogeneic skin grafts and totally inhibits T-cell proliferation in LFA-1-deficient mice.
Malm H; Corbascio M; Osterholm C; Cowan S; Larsen CP; Pearson TC; Ekberg H
Transplantation; 2002 Jan; 73(2):293-7. PubMed ID: 11821746
[TBL] [Abstract][Full Text] [Related]
12. CTLA4-Ig inhibits rejection of mouse liver allografts from Flt3-ligand-treated donors and is associated with increased lymphocyte apoptosis.
Li W; Lu L; Wang Z; Wang L; Thomson A; Fung J; Qian S
Transplant Proc; 2001; 33(1-2):246-7. PubMed ID: 11266801
[No Abstract] [Full Text] [Related]
13. The new immunology--the end of immunosuppressive drug therapy?
Schwartz RS
N Engl J Med; 1999 Jun; 340(22):1754-6. PubMed ID: 10352169
[No Abstract] [Full Text] [Related]
14. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule.
Linsley PS; Wallace PM; Johnson J; Gibson MG; Greene JL; Ledbetter JA; Singh C; Tepper MA
Science; 1992 Aug; 257(5071):792-5. PubMed ID: 1496399
[TBL] [Abstract][Full Text] [Related]
15. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells.
Abrams JR; Kelley SL; Hayes E; Kikuchi T; Brown MJ; Kang S; Lebwohl MG; Guzzo CA; Jegasothy BV; Linsley PS; Krueger JG
J Exp Med; 2000 Sep; 192(5):681-94. PubMed ID: 10974034
[TBL] [Abstract][Full Text] [Related]
16. CTLA4Ig: effects on cellular and humoral immunity and macrophage activation.
Schaub M; Stadlbauer TH; Sayegh MH
Exp Nephrol; 1997; 5(5):370-4. PubMed ID: 9386972
[No Abstract] [Full Text] [Related]
17. Inducing unresponsiveness by the use of anti-CD3 immunotoxin, CTLA4-Ig, and anti-CD40 ligand.
Knechtle SJ; Kirk AD; Fechner JH; Hong X; Dong Y; Hamawy MM; Harlan DM
Transplant Proc; 1999 May; 31(3B Suppl):27S-28S. PubMed ID: 10330966
[No Abstract] [Full Text] [Related]
18. Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection.
Azuma H; Chandraker A; Nadeau K; Hancock WW; Carpenter CB; Tilney NL; Sayegh MH
Proc Natl Acad Sci U S A; 1996 Oct; 93(22):12439-44. PubMed ID: 8901600
[TBL] [Abstract][Full Text] [Related]
19. Mounting a targeted strike on unwanted immune responses.
Cohen J
Science; 1992 Aug; 257(5071):751. PubMed ID: 1323142
[No Abstract] [Full Text] [Related]
20. Agonistic and antagonistic interactions between CTLA4Ig and donor alloantigens in sensitized rat recipients of cardiac allografts.
Onodera K; Chandraker A; Korom S; Stadlbauer TH; Kato K; Kasai S; Sayegh MH; Kupiec-Weglinski JW
Transplant Proc; 1998 Feb; 30(1):16-8. PubMed ID: 9474943
[No Abstract] [Full Text] [Related]
[Next] [New Search]
